ITI Pharma & Healthcare Growth Direct Plan
SIP amount
Min. ₹500
Lumpsum amount
Min. ₹5,000

ITI Pharma & Healthcare Growth Direct Plan

NAV
₹14.1816
-0.75%
(24 May)
AUM
162 Cr
TER
0.43%
Risk
Very High Risk
Insights
Total Expense Ratio (TER) is in the bottom 25% of comparable funds
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+110.2%
+110.0%
+104.2%
+88.5%
+45.4%
3Y
+41.8%
+42.6%
+43.7%
+40.2%
NA
5Y
+26.5%
+31.8%
NA
+28.7%
NA
ALL
+13.6%
+19.4%
+35.5%
+17.5%
+14.8%
VOL
19.9%
19.0%
21.8%
19.0%
12.3%
TER
0.9%
0.9%
0.5%
1.2%
0.4%
AUM
₹2,352 Cr
₹957 Cr
₹4,115 Cr
₹5,043 Cr
₹162 Cr
INFO
0.68
1.02
1.63
0.92
1.20
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
ITI Pharma & Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 30th Apr
Top holdings
Sun Pharmaceuticals Industries Ltd
15.8%
Max Healthcare Institute Ltd Ordinary Shares
6.2%
Lupin Ltd
6.1%
Dr Reddy's Laboratories Ltd
5.4%
Mankind Pharma Ltd
5.1%
Apollo Hospitals Enterprise Ltd
4.8%
Suven Pharmaceuticals Ltd
4.4%
Divi's Laboratories Ltd
4.1%
Zydus Lifesciences Ltd
3.6%
Laurus Labs Ltd
2.9%
Top industry exposure
Healthcare
95.4%
Basic Materials
3.3%
Other information
Minimum SIP
₹500
Minimum lumpsum
₹5,000
Additional lumpsum
₹1,000
Portfolio turnover
57%
Lock-in period
-
Exit load
• 1% for redemption within 365 days
Fund objective
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Fund manager(s)
Dhimant Shah
Rohan Korde

FAQs